The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies
release_dolq63xu2fd2pipls33o3luhs4
by
Antonella Fattorusso,
Sara Matricardi,
Elisabetta Mencaroni,
Giovanni Battista Dell'Isola,
Giuseppe Di Cara,
Pasquale Striano,
Alberto Verrotti
Abstract
Epilepsy is one of the most common neurological chronic disorders, with an estimated prevalence of 0. 5 – 1%. Currently, treatment options for epilepsy are predominantly based on the administration of symptomatic therapy. Most patients are able to achieve seizure freedom by the first two appropriate drug trials. Thus, patients who cannot reach a satisfactory response after that are defined as pharmacoresistant. However, despite the availability of more than 20 antiseizure medications (ASMs), about one-third of epilepsies remain drug-resistant. The heterogeneity of seizures and epilepsies, the coexistence of comorbidities, and the broad spectrum of efficacy, safety, and tolerability related to the ASMs, make the management of these patients actually challenging. In this review, we analyze the most relevant clinical and pathogenetic issues related to drug-resistant epilepsy, and then we discuss the current evidence about the use of available ASMs and the alternative non-pharmacological approaches.
In application/xml+jats
format
Archived Files and Locations
application/pdf
381.2 kB
file_ubj7opdwqbeuncbylnddqyug3a
|
fjfsdata01prod.blob.core.windows.net (web) web.archive.org (webarchive) |
Web Captures
https://www.frontiersin.org/articles/10.3389/fneur.2021.674483/full
2022-06-15 22:15:04 | 28 resources webcapture_vlkoi5iuvvcvjdsw5tekacuv7y
|
web.archive.org (webarchive) |
article-journal
Stage
published
Date 2021-06-22
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:
1664-2295
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar